More than 40% of pancreatic ductal adenocarcinoma (PDAC) patients have glucose intolerance or diabetes. The association has led to two hypotheses: PDAC causes diabetes or diabetes shares risk factors for the development of PDAC. In order to elucidate the relationship between diabetes and PDAC, we investigated the glucose metabolism during tumorigenesis in the LSL-KrasG12D/+; LSL-Trp53R172H/+; and Pdx-1-Cre (KPC) mouse, a genetically engineered model of PDAC.
Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer / Pasquale, Valentina; Dugnani, Erica; Liberati, Daniela; Marra, Paolo; Citro, Antonio; Canu, Tamara; Policardi, Martina; Valla, Libera; Esposito, Antonio; Piemonti, Lorenzo. - In: ACTA DIABETOLOGICA. - ISSN 0940-5429. - (2019). [Epub ahead of print] [10.1007/s00592-019-01335-4]
Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer
Esposito, Antonio;Piemonti, Lorenzo
Ultimo
2019-01-01
Abstract
More than 40% of pancreatic ductal adenocarcinoma (PDAC) patients have glucose intolerance or diabetes. The association has led to two hypotheses: PDAC causes diabetes or diabetes shares risk factors for the development of PDAC. In order to elucidate the relationship between diabetes and PDAC, we investigated the glucose metabolism during tumorigenesis in the LSL-KrasG12D/+; LSL-Trp53R172H/+; and Pdx-1-Cre (KPC) mouse, a genetically engineered model of PDAC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
